Chronic Inflammation as a Potential Predictive Factor of
Nivolumab Therapy in Non-small Cell Lung Cancer

J 2018

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

SVATON, Martin, Milada ZEMANOVA, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Vitezslav KOLEK et. al.

Základní údaje

Originální název

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Autoři

SVATON, Martin (203 Česká republika, garant), Milada ZEMANOVA (203 Česká republika), Jana SKŘIČKOVÁ (203 Česká republika, domácí), Lenka JAKUBÍKOVÁ (203 Česká republika, domácí), Vitezslav KOLEK (203 Česká republika), Juraj KULTAN (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Alzbeta BEJCKOVA (203 Česká republika), Frantisek SALAJKA (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), David VRANA (203 Česká republika), Marek KONECNY (203 Česká republika), Renata CHLOUPKOVÁ (203 Česká republika, domácí) a Milos PESEK (203 Česká republika)

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2018, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.935

Kód RIV

RIV/00216224:14110/18:00105799

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/anticanres.13048

UT WoS

000451742800023

Klíčová slova anglicky

Nivolumab; non-small cell lung cancer; overall survival; progression-free survival; biomarker

Štítky

14110215, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 13:49, Soňa Böhmová

Anotace

V originále

Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.

Citovat

SVATON, Martin, Milada ZEMANOVA, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Vitezslav KOLEK, Juraj KULTAN, Leona KOUBKOVA, Alzbeta BEJCKOVA, Frantisek SALAJKA, Michal HRNCIARIK, Bohuslav MELICHAR, David VRANA, Marek KONECNY, Renata CHLOUPKOVÁ a Milos PESEK. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. Anticancer Research. Athens: International Institute of Anticancer Research, 2018, roč. 38, č. 12, s. 6771-6782. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13048.

@article{1489189,
   author = {Svaton, Martin and Zemanova, Milada and Skřičková, Jana and Jakubíková, Lenka and Kolek, Vitezslav and Kultan, Juraj and Koubkova, Leona and Bejckova, Alzbeta and Salajka, Frantisek and Hrnciarik, Michal and Melichar, Bohuslav and Vrana, David and Konecny, Marek and Chloupková, Renata and Pesek, Milos},
   article_location = {Athens},
   article_number = {12},
   doi = {http://dx.doi.org/10.21873/anticanres.13048},
   keywords = {Nivolumab; non-small cell lung cancer; overall survival; progression-free survival; biomarker},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer},
   volume = {38},
   year = {2018}
}

TY  - JOUR
ID  - 1489189
AU  - Svaton, Martin - Zemanova, Milada - Skřičková, Jana - Jakubíková, Lenka - Kolek, Vitezslav - Kultan, Juraj - Koubkova, Leona - Bejckova, Alzbeta - Salajka, Frantisek - Hrnciarik, Michal - Melichar, Bohuslav - Vrana, David - Konecny, Marek - Chloupková, Renata - Pesek, Milos
PY  - 2018
TI  - Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
JF  - Anticancer Research
VL  - 38
IS  - 12
SP  - 6771-6782
EP  - 6771-6782
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Nivolumab
KW  - non-small cell lung cancer
KW  - overall survival
KW  - progression-free survival
KW  - biomarker
N2  - Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
ER  -

SVATON, Martin, Milada ZEMANOVA, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Vitezslav KOLEK, Juraj KULTAN, Leona KOUBKOVA, Alzbeta BEJCKOVA, Frantisek SALAJKA, Michal HRNCIARIK, Bohuslav MELICHAR, David VRANA, Marek KONECNY, Renata CHLOUPKOVÁ a Milos PESEK. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2018, roč.~38, č.~12, s.~6771-6782. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13048.

Podrobný výpis o publikaci